Theramutein modultors
AssigneeHMI Medical Innovations, LLC
InventorGerard M. HOUSEY
Life of this patent
Estimating the term…
Abstract
This invention relates to agents that are inhibitors or activators of variant forms of endogenous proteins and novel methods of identifying such variants. Of particular interest are inhibitors and activators of endogenous protein variants, encoded by genes which have mutated, which variants often arise or are at least first identified as having arisen following exposure to a chemical agent which is known to be an inhibitor or activator of the corresponding unmutated endogenous protein.
Claims3
1-53. (canceled)
A method for determining whether a substance is a specific inhibitor or specific activator of a theramutein, which comprises:
- a) providing a test cell which expresses the theramutein and which gives rise to a detectable phenoresponse;
- b) treating the test cell with the substance;
- c) examining the treated cell to determine whether the phenoresponse is modulated by treatment with the substance.
55-64. (canceled)
Dependencies are inferred from the claim text.